8th Sep 2014 07:17
LONDON (Alliance News) - Skyepharma PLC Monday said that its partner Mundipharma International Corporation Ltd had announced results from a Phase III study of its Flutiform treatment for paediatric asthma at the European Respiratory Society in Munich, Germany.
The study showed the efficacy and tolerability of the treatment in children with asthma between the ages of five to twelve, the company said.
The results showed that Flutiform was superior to fluticasone propionate, and non-inferior compared to a combination fluticasone propionate/salmeterol treatment for the primary endpoint of the study. It also showed it has a similar tolerability profile to the other treatments.
Mundipharma is licensed by Skyepharma as the authorised distributor of Flutiform in Europe and most other territories outside of Japan and the Americas.
Shares in Skyepharma were trading up 0.2% at 309.00 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
SKP.L